Ezrin和RhoA蛋白在鼻咽癌組織中的表達(dá)及臨床意義
發(fā)布時(shí)間：2018-11-03 12:41
【摘要】： 目的：檢測(cè)Ezrin和RhoA蛋白各自在不同臨床分期鼻咽癌(Nasopharyngeal Carcinoma, NPC)組織中的表達(dá),探討二者在NPC發(fā)生和發(fā)展中的作用以及它們?cè)谄渲械南嗷リP(guān)系。為NPC浸潤(rùn)轉(zhuǎn)移的機(jī)制提供新的理論依據(jù)。為NPC的早期診斷、臨床防治及預(yù)后判斷提供新的有價(jià)值的指標(biāo)。 方法： 1.選取有完整臨床資料及隨訪資料的150例NPC病例石蠟包埋組織標(biāo)本作為實(shí)驗(yàn)組,選取20例鼻咽粘膜慢性炎石蠟包埋組織作為對(duì)照。 2.應(yīng)用免疫組化Supervision二步法分別檢測(cè)NPC和對(duì)照組組織中Ezrin和RhoA蛋白的表達(dá)情況。 3.采用SPSS13.0統(tǒng)計(jì)軟件進(jìn)行數(shù)據(jù)處理。用x2檢驗(yàn)、Spearman等級(jí)相關(guān)分析法分析Ezrin和RhoA蛋白表達(dá)與NPC患者臨床病理特征之間的關(guān)系；用Kaplan-Meier法進(jìn)行單因素生存分析,log-rank法進(jìn)行樣本間生存率曲線差異檢驗(yàn)。 結(jié)果： 1. Ezrin與RhoA蛋白在NPC組織中的陽(yáng)性表達(dá)率分別為74.7%和62.7%,在對(duì)照組組織中基本不表達(dá)。兩組差異都有非常顯著統(tǒng)計(jì)學(xué)意義(均為PO.001)。 2. Ezrin與RhoA蛋白陽(yáng)性表達(dá)率在NPC臨床TNM分期的T1、T2、T3、T4分別為：29.4%、65.5%、92.3%、88.5%和17.6%、52.7%、78.8%、80.8%,除T3與T4期,各T分期之間比較均有顯著或非常顯著統(tǒng)計(jì)學(xué)意義(P0.05或P0.001)；在N0、N1、N2、N3分別為53.8%、71.4%、79.6%、87.9%和46.2%、54.8%、65.3%、81.8%,Ezrin蛋白表達(dá)在N0與N2,N0與N3分期之間有顯著差異(P0.05),RhoA蛋白表達(dá)在N0與N1,N0與N3以及N1與N3分期之間有顯著差異(P0.05)；在M0與M1分別為72.5%、94.7%和60.3%、84.2%, M0與M1之間比較均有顯著統(tǒng)計(jì)學(xué)意義(均為P0.05)。 3. Ezrin與RhoA蛋白陽(yáng)性表達(dá)率在臨床分期Ⅰ、Ⅱ、Ⅲ、Ⅳ期中分別為50%、40%、80.7%、86.9%和0%、26.7%、64.9%、80.3%,兩指標(biāo)各期之間均有非常顯著統(tǒng)計(jì)學(xué)意義(均為P0.001)。 4.NPC組織中Ezrin與RhoA兩者表達(dá)呈顯著正相關(guān)(Rs=0.486,P0.001)。 5. Ezrin和RhoA蛋白表達(dá)陽(yáng)性的患者,治療后1年、3年及5年生存率分別為：75%,55%,33%和84%,60%,33%,均低于陰性表達(dá)100%,92%,78%和93%,71%,63%。均有顯著性差異(x2=12.943,P=0.000及x2=9.869,P=0.0020.05)。 結(jié)論： 1. Ezrin和RhoA蛋白表達(dá)均與NPC的發(fā)生可能有關(guān),但更可能是Ezrin和RhoA蛋白表達(dá)的NPC細(xì)胞本身具有浸潤(rùn)轉(zhuǎn)移潛能。 2. Ezrin和RhoA蛋白表達(dá)均參與了NPC的早期局部浸潤(rùn)轉(zhuǎn)移、淋巴結(jié)轉(zhuǎn)移和遠(yuǎn)處器官轉(zhuǎn)移等過(guò)程,并很有可能是重要的參與因子。 3. Ezrin與RhoA蛋白表達(dá)呈顯著正相關(guān),進(jìn)一步間接證明了兩者在結(jié)構(gòu)、功能上和基因表達(dá)等方面有著密切聯(lián)系,同時(shí)表明它們很可能為NPC浸潤(rùn)轉(zhuǎn)移的共同或協(xié)同促進(jìn)因子。 4. Ezrin和RhoA與NPC的預(yù)后有關(guān)。Ezrin或RhoA陽(yáng)性表達(dá)的NPC患者平均生存率低,特別是Ezrin和RhoA同時(shí)陽(yáng)性表達(dá)者較Ezrin和RhoA同時(shí)陰性表達(dá)者生存期短,預(yù)后差。
[Abstract]:Aim: to detect the expression of Ezrin and RhoA proteins in (Nasopharyngeal Carcinoma, NPC) tissues of nasopharyngeal carcinoma at different clinical stages and to explore their roles in the pathogenesis and development of NPC and their relationship. It provides a new theoretical basis for the mechanism of NPC invasion and metastasis. To provide a new valuable index for early diagnosis, clinical prevention and prognosis of NPC. Methods: 1. Paraffin embedded tissue specimens of 150 cases of NPC with complete clinical data and follow-up data were selected as experimental group and 20 cases of nasopharyngeal mucosa chronic inflammation paraffin embedded tissue as control group. 2. The expression of Ezrin and RhoA in NPC and control group was detected by immunohistochemical Supervision two-step method. 3. SPSS13.0 statistical software is used for data processing. The relationship between the expression of Ezrin and RhoA protein and the clinicopathological characteristics of NPC patients was analyzed by x2 test and Spearman rank correlation analysis. Results: 1. The positive expression rates of Ezrin and RhoA in NPC were 74.7% and 62.7%, respectively. The differences between the two groups were statistically significant (both PO.001). 2. The positive expression rate of Ezrin and RhoA protein in clinical TNM stage of NPC was 29.4% and 65.5%, respectively. The positive expression rate of Ezrin and RhoA protein was 88.8% and 52.7%, respectively, except T 3 and T 4, respectively, with the exception of T 3 and T 4, and T 3, T 4, T 3 and T 4, respectively. There were significant or very significant statistical differences among T stages (P0.05 or P0.001). At N0, N1, N2N3 was 53.81.41, and 79.6% and 46.2%, 54.8and 65.3%, respectively, and the Ezrin protein was expressed in N0 and N2, and the Ezrin protein was expressed in N0 and N2. There was significant difference between N0 and N3 stages (P0.05). The expression of), RhoA protein was significantly different between N0 and N1N0 and N3 and N1 and N3 stages (P0.05). M0 and M1 were 72.5% and 60.3%, respectively, and there were significant differences between M0 and M1 (P0.05). 3. The positive expression rates of Ezrin and RhoA protein in clinical stages 鈪，
本文編號(hào)：2307823
[Abstract]:Aim: to detect the expression of Ezrin and RhoA proteins in (Nasopharyngeal Carcinoma, NPC) tissues of nasopharyngeal carcinoma at different clinical stages and to explore their roles in the pathogenesis and development of NPC and their relationship. It provides a new theoretical basis for the mechanism of NPC invasion and metastasis. To provide a new valuable index for early diagnosis, clinical prevention and prognosis of NPC. Methods: 1. Paraffin embedded tissue specimens of 150 cases of NPC with complete clinical data and follow-up data were selected as experimental group and 20 cases of nasopharyngeal mucosa chronic inflammation paraffin embedded tissue as control group. 2. The expression of Ezrin and RhoA in NPC and control group was detected by immunohistochemical Supervision two-step method. 3. SPSS13.0 statistical software is used for data processing. The relationship between the expression of Ezrin and RhoA protein and the clinicopathological characteristics of NPC patients was analyzed by x2 test and Spearman rank correlation analysis. Results: 1. The positive expression rates of Ezrin and RhoA in NPC were 74.7% and 62.7%, respectively. The differences between the two groups were statistically significant (both PO.001). 2. The positive expression rate of Ezrin and RhoA protein in clinical TNM stage of NPC was 29.4% and 65.5%, respectively. The positive expression rate of Ezrin and RhoA protein was 88.8% and 52.7%, respectively, except T 3 and T 4, respectively, with the exception of T 3 and T 4, and T 3, T 4, T 3 and T 4, respectively. There were significant or very significant statistical differences among T stages (P0.05 or P0.001). At N0, N1, N2N3 was 53.81.41, and 79.6% and 46.2%, 54.8and 65.3%, respectively, and the Ezrin protein was expressed in N0 and N2, and the Ezrin protein was expressed in N0 and N2. There was significant difference between N0 and N3 stages (P0.05). The expression of), RhoA protein was significantly different between N0 and N1N0 and N3 and N1 and N3 stages (P0.05). M0 and M1 were 72.5% and 60.3%, respectively, and there were significant differences between M0 and M1 (P0.05). 3. The positive expression rates of Ezrin and RhoA protein in clinical stages 鈪，
本文編號(hào)：2307823
本文鏈接：http://www.sikaile.net/yixuelunwen/yank/2307823.html
最近更新
教材專著
